Circulating Carnosine Dipeptidase 1 associates with weight loss and poor prognosis in gastrointestinal cancer

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Arner, Peter ^a   Henjes, Frauke ^b   Schwenk, Jochen M ^b   Darmanis, Spyros ^b   Dahlman, Ingrid ^a   Iresjö, Britt Marie ^c   Naredi, Peter ^c   Agustsson, Thorhallur ^d   Lundholm, Kent ^c   Nilsson, Peter ^b   Rydén, Mikael ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b SCIENCE FOR LIFE LABORATORY   (Sweden)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d STOCKHOLM SÖDER HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CARNOSINE DIPEPTIDASE 1; DIPEPTIDASE; SOMATOMEDIN C; UNCLASSIFIED DRUG; CNDP1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; BLOOD ANALYSIS; CACHEXIA; CANCER PROGNOSIS; CATABOLISM; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; DISEASE ASSOCIATION; ENZYME BLOOD LEVEL; ENZYME IMMUNOASSAY; FEMALE; GLIOBLASTOMA; HUMAN; MALE; MALNUTRITION; METASTASIS; OUTCOME ASSESSMENT; PROSTATE CANCER; PROTEOMICS; QUALITY OF LIFE; VALIDATION PROCESS; WEIGHT REDUCTION; ADENOCARCINOMA; AGED; BLOOD; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; STOMACH TUMOR; SURVIVAL ANALYSIS;

ADENOCARCINOMA; AGED; BIOMARKERS, TUMOR; CACHEXIA; COHORT STUDIES; DIPEPTIDASES; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL ANALYSIS;

EID: 84928571516     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0123566     Document Type: Article

References (44)

1. Wallengren O, Lundholm K, Bosaeus I. Diagnostic criteria of cancer cachexia: relation to quality of life, exercise capacity and survival in unselected palliative care patients. Support Care Cancer 2013; 21: 1569-1577. doi: 10.1007/s00520-012-1697-z PMID: 23314651
2. Evans WJ, Morley JE, Argiles J, Bales C, Baracos V, Guttridge D, et al. Cachexia: a new definition. Clin Nutr 2008; 27: 793-799. doi: 10.1016/j.clnu.2008.06.013 PMID: 18718696
3. Bosaeus I, Daneryd P, Svanberg E, Lundholm K. Dietary intake and resting energy expenditure in relation to weight loss in unselected cancer patients. Int J Cancer 2001; 93: 380-383. PMID: 11433403
4. Lainscak M, Filippatos GS, Gheorghiade M, Fonarow GC, Anker SD. Cachexia: common, deadly, with an urgent need for precise definition and new therapies. Am J Cardiol 2008; 101: 8E-10E. doi: 10. 1016/j.amjcard.2008.02.065 PMID: 18514632
5. Lundholm K, Korner U, Gunnebo L, Sixt-Ammilon P, Fouladiun M, Daneryd P, et al. Insulin treatment in cancer cachexia: effects on survival, metabolism, and physical functioning. Clin Cancer Res 2007; 13: 2699-2706. PMID: 17473202
6. Lundholm K, Gunnebo L, Korner U, Iresjo BM, Engstrom C, Hyltander A, et al. Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study. Cancer 2010; 116: 2044-2052. doi: 10.1002/cncr.24917 PMID: 20186829
7. Lindholm E, Daneryd P, Korner U, Hyltander A, Fouladiun M, Lundholm K. Effects of recombinant erythropoietin in palliative treatment of unselected cancer patients. Clin Cancer Res 2004; 10: 6855-6864. PMID: 15501962
8. Lundholm K, Daneryd P, Bosaeus I, Korner U, Lindholm E. Palliative nutritional intervention in addition to cyclooxygenase and erythropoietin treatment for patients with malignant disease: Effects on survival, metabolism, and function. Cancer 2004; 100: 1967-1977. PMID: 15112279
9. Tisdale MJ. Mechanisms of cancer cachexia. Physiol Rev 2009; 89: 381-410. doi: 10.1152/physrev.00016.2008 PMID: 19342610
10. Ryden M, Arner P. Fat loss in cachexia-is there a role for adipocyte lipolysis? Clin Nutr 2007; 26: 1-6. PMID: 17095126
11. Fouladiun M, Korner U, Bosaeus I, Daneryd P, Hyltander A, Lundholm KG. Body composition and time course changes in regional distribution of fat and lean tissue in unselected cancer patients on palliative care-correlations with food intake, metabolism, exercise capacity, and hormones. Cancer 2005; 103: 2189-2198. PMID: 15822132
12. Arner P. Medicine. Lipases in cachexia. Science 2011; 333: 163-164. doi: 10.1126/science.1209418 PMID: 21737725
13. Laurencikiene J, Stenson BM, Arvidsson Nordstrom E, Agustsson T, Langin D, Isaksson B, et al. Evidence for an important role of CIDEA in human cancer cachexia. Cancer Res 2008; 68: 9247-9254. doi: 10.1158/0008-5472.CAN-08-1343 PMID: 19010897
14. Tisdale MJ. The 'cancer cachectic factor'. Support Care Cancer 2003; 11: 73-78. PMID: 12560934
15. Ryden M, Agustsson T, Andersson J, Bolinder J, Toft E, Arner P. Adipose zinc-alpha2-glycoprotein is a catabolic marker in cancer and noncancerous states. J Intern Med 2011.
16. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002; 1: 845-867. PMID: 12488461
17. Stoevesandt O, Taussig MJ. Affinity proteomics: the role of specific binding reagents in human proteome analysis. Expert Rev Proteomics 2012; 9: 401-414. doi: 10.1586/epr.12.34 PMID: 22967077
18. Uhlen M, Oksvold P, Fagerberg L, Lundberg E, Jonasson K, Forsberg M, et al. Towards a knowledge-based Human Protein Atlas. Nat Biotechnol 2010; 28: 1248-1250. doi: 10.1038/nbt1210-1248 PMID: 21139605
19. Gautam P, Nair SC, Gupta MK, Sharma R, Polisetty RV, Uppin MS, et al. Proteins with altered levels in plasma from glioblastoma patients as revealed by iTRAQ-based quantitative proteomic analysis. PLoS ONE 2012; 7: e46153. doi: 10.1371/journal.pone.0046153 PMID: 23029420
20. Schwenk JM, Igel U, Neiman M, Langen H, Becker C, Bjartell A, et al. Toward next generation plasma profiling via heat-induced epitope retrieval and array-based assays. Mol Cell Proteomics 2010; 9: 2497-2507. doi: 10.1074/mcp.M110.001560 PMID: 20682762
21. Agustsson T, Ryden M, Hoffstedt J, van Harmelen V, Dicker A, Laurencikiene J, et al. Mechanism of increased lipolysis in cancer cachexia. Cancer Res 2007; 67: 5531-5537. PMID: 17545636
22. Ljungman D, Hyltander A, Lundholm K. Cost-utility estimations of palliative care in patients with pancreatic adenocarcinoma: a retrospective analysis. World J Surg 2013; 37: 1883-1891. doi: 10.1007/s00268-013-2003-z PMID: 23519293
23. Ottery FD. Definition of standardized nutritional assessment and interventional pathways in oncology. Nutrition 1996; 12: S15-19. PMID: 8850213
24. Hellmer J, Marcus C, Sonnenfeld T, Arner P. Mechanisms for differences in lipolysis between human subcutaneous and omental fat cells. J Clin Endocrinol Metab 1992; 75: 15-20. PMID: 1320047
25. Uhlen M, Bjorling E, Agaton C, Szigyarto CA, Amini B, Andersen E, et al. A human protein atlas for normal and cancer tissues based on antibody proteomics. Mol Cell Proteomics 2005; 4: 1920-1932. PMID: 16127175
26. Qundos U, Johannesson H, Fredolini C, O'Hurley G, Branca R, Uhlén M, et al. Analysis of plasma from prostate cancer patients links decreased carnosine dipeptidase 1 levels to lymph node metastasis. Translational Proteomics 2014; 2: 14-24.
27. Braoudaki M, Lambrou GI, Vougas K, Karamolegou K, Tsangaris GT, Tzortzatou-Stathopoulou F. Protein biomarkers distinguish between high- and low-risk pediatric acute lymphoblastic leukemia in a tissue specific manner. J Hematol Oncol 2013; 6: 52. doi: 10.1186/1756-8722-6-52 PMID: 23849470
28. Li L, Xu Y, Yu CX. Proteomic analysis of serum of women with elevated Ca-125 to differentiate malignant from benign ovarian tumors. Asian Pac J Cancer Prev 2012; 13: 3265-3270. PMID: 22994745
29. Dieplinger H, Ankerst DP, Burges A, Lenhard M, Lingenhel A, Fineder L, et al. Afamin and apolipoprotein A-IV: novel protein markers for ovarian cancer. Cancer Epidemiol Biomarkers Prev 2009; 18: 1127-1133. doi: 10.1158/1055-9965.EPI-08-0653 PMID: 19336561
30. Schwenk JM, Igel U, Kato BS, Nicholson G, Karpe F, Uhlen M, et al. Comparative protein profiling of serum and plasma using an antibody suspension bead array approach. Proteomics 2010; 10: 532-540. doi: 10.1002/pmic.200900657 PMID: 19953555
31. Teufel M, Saudek V, Ledig JP, Bernhardt A, Boularand S, Carreau A, et al. Sequence identification and characterization of human carnosinase and a closely related non-specific dipeptidase. J Biol Chem 2003; 278: 6521-6531. PMID: 12473676
32. Adelmann K, Frey D, Riedl E, Koeppel H, Pfister F, Peters V, et al. Different conformational forms of serum carnosinase detected by a newly developed sandwich ELISA for the measurements of carnosinase concentrations. Amino Acids 2012; 43: 143-151. doi: 10.1007/s00726-012-1244-8 PMID: 22349764
33. Lenney JF, George RP, Weiss AM, Kucera CM, Chan PW, Rinzler GS. Human serum carnosinase: characterization, distinction from cellular carnosinase, and activation by cadmium. Clin Chim Acta 1982; 123: 221-231. PMID: 7116644
34. Barski OA, Xie Z, Baba SP, Sithu SD, Agarwal A, Cai J, et al. Dietary carnosine prevents early atherosclerotic lesion formation in apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 2013; 33: 1162-1170. doi: 10.1161/ATVBAHA.112.300572 PMID: 23559625
35. Mong MC, Chao CY, Yin MC. Histidine and carnosine alleviated hepatic steatosis in mice consumed high saturated fat diet. Eur J Pharmacol 2011; 653: 82-88. doi: 10.1016/j.ejphar.2010.12.001 PMID: 21167151
36. Janssen B, Hohenadel D, Brinkkoetter P, Peters V, Rind N, Fischer C, et al. Carnosine as a protective factor in diabetic nephropathy: association with a leucine repeat of the carnosinase gene CNDP1. Diabetes 2005; 54: 2320-2327. PMID: 16046297
37. Mooyaart AL, Zutinic A, Bakker SJ, Grootendorst DC, Kleefstra N, van Valkengoed IG, et al. Association between CNDP1 genotype and diabetic nephropathy is sex specific. Diabetes 2010; 59: 1555-1559. doi: 10.2337/db09-1377 PMID: 20332346
38. Ahluwalia TS, Lindholm E, Groop LC. Common variants in CNDP1 and CNDP2, and risk of nephropathy in type 2 diabetes. Diabetologia 2011; 54: 2295-2302. doi: 10.1007/s00125-011-2178-5 PMID: 21573905
39. Zhu JM, Wang B, Li J, Chen GM, Fan YG, Feng CC, et al. D18S880 microsatellite polymorphism of carnosinase gene and diabetic nephropathy: a meta-analysis. Genet Test Mol Biomarkers 2013; 17: 289-294. doi: 10.1089/gtmb.2012.0341 PMID: 23402577
40. Gaunitz F, Hipkiss AR. Carnosine and cancer: a perspective. Amino Acids 2012; 43: 135-142. doi: 10.1007/s00726-012-1271-5 PMID: 22454085
41. Renner C, Zemitzsch N, Fuchs B, Geiger KD, Hermes M, Hengstler J, et al. Carnosine retards tumor growth in vivo in an NIH3T3-HER2/neu mouse model. Mol Cancer 2010; 9: 2. doi: 10.1186/1476-4598- 9-2 PMID: 20053283
42. Iovine B, Iannella ML, Nocella F, Pricolo MR, Bevilacqua MA. Carnosine inhibits KRAS-mediated HCT116 proliferation by affecting ATP and ROS production. Cancer Lett 2012; 315: 122-128. doi: 10. 1016/j.canlet.2011.07.021 PMID: 22137144
43. Nagai K, Suda T. [Antineoplastic effects of carnosine and beta-alanine-physiological considerations of its antineoplastic effects]. Nihon Seirigaku Zasshi 1986; 48: 741-747. PMID: 3102721
44. Dahlman I, Mejhert N, Linder K, Agustsson T, Mutch DM, Kulyte A, et al. Adipose tissue pathways involved in weight loss of cancer cachexia. Br J Cancer 2010; 102: 1541-1548. doi: 10.1038/sj.bjc.6605665 PMID: 20407445